Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Marek’s disease and avian influenza vaccine developed
Scientists inserted avian influenza into the turkey herpesvirus that is used in Marek's disease vaccines.

Gene-editing technique faster than previous methods

A vaccine that offers birds protection against Marek’s disease and avian influenza has been developed by scientists at The Pirbright Institute.


Writing in the journal Vaccines, scientists describe how they used a gene-editing technique (CRISPR/Cas9 ) to insert avian influenza into the turkey herpesvirus (HVT) that is used in Marek’s disease vaccines.


The gene codes for haemagglutinin (HA) - an influenza protein that plays a vital role in the virus’ ability to infect host cells and a key target of the host immune response to block infection.


Professor Munir Iqbal, head of the Avian Influenza group at Pirbright, explains: “HVT is already widely used in vaccines against Marek’s disease and can be administered to eggs, enabling automated delivery and providing birds with protection from the day they hatch.

“The additional HA gene we have incorporated will be expressed by HVT when it replicates in host cells, meaning that a single dose of vaccine induces immunity against both viruses."


Compared to previous methods, the new technique is faster, more efficient, and will reduce the time it takes for poultry producers to update vaccine strains. This will enable a quicker response to disease outbreaks and provide better protection.


Prof Iqbal continued: “The genetic engineering process we have developed using CRISPR/Cas9 is far quicker and more efficient than previous technologies, as well as being very consistent and accurate. These attributes are essential for providing fast and reliable vaccine production to protect poultry.


“Improving how we make vaccines is critical for preventing avian influenza outbreaks. Our work could help reduce the spread of disease between birds and reduce the risk of infection for people who work closely with poultry."

Become a member or log in to add this story to your CPD history

Voting opens for BEVA Council

News Story 1
 Eligible members of BEVA will be able to vote for their Council team until Monday, 17 August 2026. Members will have received an election email on 17 July.

There are five candidates standing for four available places on Council. They are:

  • Alexandre Triguino
  • Angela Jones
  • Beth Bryant
  • Holly Rees
  • Hugh Somerville
Full profiles for each candidate can be found on the BEVA website

Click here for more...
News Shorts
Government releases latest bluetongue statistics

APHA has confirmed the number of bluetongue cases that have been logged in the UK since 1 July 2026.

The total number of BTV-3 cases, as of 6 August, is 187. This includes 183 cases in England and four cases in Wales.

There have been no recorded cases in Scotland and Northern Ireland.

The location of premises in Great Britain where at least one animal has tested positive by PCR for BTV-3, BTV-8 or BTV-12 is available on the bluetongue case map. All livestock keepers in Great Britain are urged to familiarise themselves with nation-specific bluetongue control policies.

Bluetongue virus is a notifiable disease. It is a legal requirement that any suspicions, even if livestock has been vaccinated, are reported immediately.